((自动化翻译由路透提供，请见免责声明 ))
11月8日 - ** 制药商Ardelyx 股价下跌21%，至5.04美元
** 法院驳回了 (link) ，该公司因医疗保险和医疗补助服务中心计划将其肾病药物纳入医疗保险支付捆绑系统而对其提起的诉讼。
** 该药名为 Xphozah，去年在美国获批 (link)，用于治疗慢性肾病患者的高磷酸盐血症。
** 经纪公司杰富瑞（Jefferies）称，现在的焦点又回到了国会，以及他们能否 在未来 30 天内通过 HR-5074 (link) 。
** 该法案推迟了对用于治疗终末期肾病的口服药物的医疗保险支付方法的修改
** 今年以来股价下跌 ~17
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.